Tempus delivers insight generation at scale. Our comprehensive, AI-powered platform supports every stage of drug development—from discovery through commercialization. Heading to #ESMO26? Visit Booths #1068 & #1069 to connect with our team and explore our latest innovations. Learn more: tempus.co/4jFLmh3

Join us at #ESMO26 as we showcase novel clinical research revealing meaningful insights in cancer biology, treatment response, and patient outcomes. Visit us at booth #1068 & 1069 to experience live demos of our AI-powered technology and new product offerings designed to advance drug discovery and development. Learn more: tempus.co/4eL2IWf

"Managing the information became as exhausting as managing the illness itself." For Laura, Chief Commerical Officer at Tempus, and her daughter Sophia, navigating a chronic illness meant tracking fragmented data across multiple specialists. Watch how Olivia, our personal health concierge app, helped them consolidate their health histories, spot symptom patterns, and take back control. See their full story: youtu.be/nVTH1MuEv8Q #DysatunonomiaAwarenesssMonth

Real-Time Variant Tracker™ (RTVT), is a feature now available as a part of xM (NeXT Personal ® Dx). RTVT delivers an added layer of clarity directly within the standard report clinicians already receive, including variants associated with NCCN guideline-recommended and FDA-approved therapies. These findings providing immediate, actionable context the moment an associated signal shifts.

Study presented at #ESMO26, from our collaboration with @pfizer, evaluated more than 60,000 advanced #NSCLC cases and found greater than 80% sensitivity across all 12 biomarkers using routine H&E pathology images. Read on: tempus.co/4jpwO4X

We will report financial results for the third quarter ended September 30, 2026, before U.S. markets open on Monday, November 2, 2026. The live audio webcast will be accessible through the “Events” section of the Tempus Investor Relations website, as well as here: tempus.co/47USb73

We'll be at #ASCOQLTY26 presenting two abstracts demonstrating how Tempus Next uses agentic care-gap detection and AI-guided oncology care pathways to identify testing gaps and notify care teams. Stop by our poster sessions or connect with our team at the conference to learn more: tempus.co/4egjdJJ

We’re looking forward to seeing you at Pathology Visions '26 in San Diego. Stop by Booth #204 meet with the Tempus team and experience live demos of our digital pathology and AI offerings that enable biomarker prediction and workflow efficiency. Learn more: tempus.co/4i0IGYT @dpatweet #PathVisions26

We're proud to add to our offerings for patients with rare diseases. This offering combines whole genome sequencing, RNA analysis and ongoing reanalysis to help address diagnostic challenges and improve the ability to find and interpret answers.

The initial days following an advanced cancer diagnosis are critical for treatment planning. With Tempus Preview, clinicians may access clinically relevant predictions within ~24 hours of sample receipt. These early insights empower clinicians to anticipate targeted treatment pathways and coordinate management plans, without altering standard tissue workflows. Tempus Preview provides preliminary predictions and treatment should not be initiated until confirmatory NGS results are received. Learn more: tempus.co/4hKurbM

"AI-enabled diagnostics... [have] the potential to remove mistakes, errors, and waste that are plaguing the system. And in cancer alone... if we had a system where every patient was on the optimal therapeutic path—eliminating that trial and error, eliminating all the mistakes—I suspect we could save about 100,000 lives a year." -- Tempus CEO @lefkofsky at @WSJ's Future of Health with @Annie_Gasparro Watch the recording: tempus.co/wsj

We're honored to be listed on @FortuneMagazine's #FortuneFuture120, which recognizes companies with long-term growth potential and traits such as "the inner dynamism of their culture." This recognition is a testament to our team's relentless drive to innovate and our unwavering commitment to unlocking the power of precision medicine for patients everywhere. Read on: bit.ly/4B1DuN8

Attending #WorldADC in San Diego? Attend our live session featuring our Senior Director of Computational Discovery Science, Radia Johnson, Ph.D., as she shares how we use multimodal real-world data, organoid screens, and AI to improve target selection and test findings against patient outcomes. Schedule a meeting with the team: tempus.co/4yJEyUi

Today we announced an expanded collaboration with both @moderna_tx and @Merck to support the potential commercialization of intismeran autogene, a novel individualized neoantigen therapy. Tempus will deliver advanced NGS sequencing and sample collection workflows, combining our clinical infrastructure with mRNA innovation to help bring personalized cancer vaccines to patients at scale. Read on: tempus.com/news/pr/tempus-an…

"The hardest part of outcomes research isn't running the final analysis — it's getting from a research question to a finalized protocol without losing weeks to study design iterations." Watch as Adrienne Brackey, MS, a Senior Data Scientist at Tempus, uses Lens, our AI-enabled analytical program, to pressure-test a study design in minutes — all while outcomes stay blinded — and finalize the protocol in record time. Request a demo now: tempus.co/4yzbaQi

October is #BreastCancerAwarenessMonth, a time to honor the strength of each individual facing a diagnosis and to reflect on the power of equipping physicians with meaningful insights when decisions matter most. When Romy was diagnosed with triple-negative breast cancer, Tempus genomic testing helped arm her physician with insights that led to a targeted combination of immunotherapy and chemotherapy. She now has no evidence of disease. Learn more about Romy's story: youtube.com/watch?v=5EJGOfMu…

Join leaders from Tempus, @DaiichiSankyoUS, and @abbvie for a conversation on how specialized, multimodal foundation models are creating a single AI backbone that spans the entire drug development and commercialization lifecycle. Register now: tempus.co/4ysmFsF

We're excited to share that 13 abstracts have been accepted for presentation at #ESMO26, revealing insights in cancer biology, treatment response and patient outcomes across solid tumors, including prostate, breast, NSCLC, renal cell carcinoma and gynecologic malignancies. Read on: tempus.co/4ytiNbd

Join us for a discussion on the findings of "Multi-Center Prospective Study Evaluating an AI-Enabled Clinical Decision Support Tool To Improve Biomarker Testing in Early-Stage NSCLC," a study presented at the #ASCO26. Register now: tempus.co/4AHwNiW